Can technology increase adenoma detection rate?

Wee Sing Ngu and Colin Rees

Abstract: Colorectal cancer is the third most common cancer worldwide and the second most common cause of cancer-related death in Europe and North America. Colonoscopy is the gold standard investigation for the colon but is not perfect, and small or flat adenomas can be missed which increases the risk of patients subsequently developing colorectal cancer. Adenoma detection rate is the most widely used marker of quality, and low rates are associated with increased rates of post-colonoscopy colorectal cancer. Standards of colonoscopy and adenoma detection vary widely between different endoscopists. Interventions to improve adenoma detection rate are therefore required. Many devices have been purported to increase adenoma detection rate. This review looks at current available evidence for device technology to improve adenoma detection rate during colonoscopy.

Keywords: adenoma detection rate, colonoscopy, colorectal cancer, colorectal polyps, post-colonoscopy colorectal cancer

Received: 21 July 2017; revised manuscript accepted: 16 October 2017.

Introduction

Colorectal cancer is the third most common cancer in the world, with 1.4 million new cases diagnosed in 2012. In the United States, 134,784 cases of colorectal cancer were diagnosed in 2012, with 70,204 men and 64,580 women affected. In Europe, there were 477,000 new cases of colorectal cancer, with the United Kingdom accounting for 41,581 of these.

The majority (90%) of colorectal cancers arise from colorectal adenomas which are present in a third of European and American populations. The adenoma–carcinoma sequence is a well-established pathway by which adenomatous polyps develop into colorectal cancer.

Adenoma detection rate (ADR) is defined as the proportion of colonoscopies in which at least one adenoma is found. As a surrogate marker of mucosal visualization, it is regarded as the most important indicator of quality in colonoscopy. Low ADR is implicated as one of the primary reasons for post-colonoscopy colorectal cancers (PCCRC). Acceptable levels of ADR will depend upon the population colonosced but minimal standards should be defined.

A Polish screening study demonstrated that low ADRs were associated with higher rates of PCCRC ($p = 0.008$). In this study, colonoscopists with an ADR of $<20\%$ had a hazard ratio for PCCRC that was 10 times that of colonoscopists with an ADR of $>20\%$ (absolute risk for ADR $\geq 20\%$ 0.011% versus ADR $<20\%$ 0.115%). Another large American study of over 300,000 screening, surveillance and diagnostic colonoscopies found an inverse relationship between ADR and the risk of PCCRC, advanced-stage PCCRC and fatal PCCRC. A 1% increase in ADR was associated with a 3% reduction in the risk of PCCRC and a 5% reduction in risk of a fatal PCCRC.

A wide variability in ADR has been reported in both screening and non-screening populations. Many factors may be responsible for the variation in ADR, including: suboptimal technique; shorter withdrawal time; inadequate bowel preparation; presence of flat, depressed or subtle lesions; and the inability to visualize the proximal side of haustral folds, flexures (blind spots), rectal valves and ileocaecal valves. It has been estimated that 10% of the colonic surface is poorly seen using a standard forward-viewing colonoscope even with good bowel preparation.

Other measures used to assess diagnostic quality are polyp detection rate (PDR), advanced
adenoma detection rate (AADR), adenoma miss rate, mean adenomas per procedure (MAP) and mean adenomas per positive procedure.

PDR is easier to measure compared to ADR and correlates well with ADR in colonic segments proximal to the splenic flexure. The application of a conversion factor to the PDR may be used to accurately estimate the ADR.

AADR measures adenomas more or equal to 10 mm in size with or without the presence of vil-lous components or high-grade dysplasia. Advanced adenomas occur less frequently but have a higher malignant potential. An American observational cohort study of 1933 colonoscopies from 14 colonoscopists reported significant variations in ADR and AADR but found no correlation between them. This may be a result of an increase in small non-advanced adenomas that are counted towards ADR, as demonstrated by a German study analysing trends in ADR in a screening programme.

Missed lesions are polyps or adenomas that are missed during index colonoscopy. Adenoma miss rate is calculated by dividing the total number of adenomas found on repeat examination by the total number of adenomas found on initial and repeat examination. Data show that experienced endoscopists miss up to 6% of adenomas larger than 1 cm in size and 30% of all adenomas. The miss rate for adenomas has been quoted at up to 24%. Small adenomas (<10 mm in size) have a significantly higher miss rate compared to larger adenomas (>10 mm). Adenoma miss rate can be difficult to calculate as it requires tandem colonoscopy; therefore most studies use the ADR rate as a measure of quality in identifying and removing adenomas.

A population-based study in the Netherlands found that 57.8% of patients who had interval cancers had missed lesions at colonoscopy. In addition, they suggested that 86% of interval cancers were preventable and were due to missed lesions, inadequate examinations or surveillance. A majority of the lesions that were missed were proximally located, small in size and had a flat appearance. Variation is also seen in adenoma miss rates. One systematic review analysed six studies in which participants underwent tandem colonoscopy. The miss rate for all adenomas was 22%. Adenoma miss rates for polyps <10 mm in size were significantly higher than for adenomas measuring >10 mm.

MAP is the total number of adenomas detected divided by the number of procedures performed. Mean adenomas per positive procedure (MAP+) is the total number of adenomas detected divided by the number of procedures in which one or more adenomas have been detected. A recent study in a screening population demonstrated that ADR and MAP were positively correlated, mostly due to the fact that 53% of procedures in which adenomas were found only demonstrate one adenoma. MAP+ correlated less well with ADR.

Quality in colonoscopy

Despite variation in ADR, there has been an improving trend worldwide, with studies showing an increase in ADR in Europe, the United States and the United Kingdom. This is attributed to a number of interventions, with the first being improved endoscopy training. A study investigating adenoma miss rates in patients undergoing tandem colonoscopy by a trainee followed immediately by an experienced endoscopist indicated that adenoma miss rates improved with experience of the trainee.

There is also an increased awareness of quality improvement measures that can be utilized to improve AADR as a whole. These measures may include improving bowel preparation, having longer withdrawal times, using hyoscine-n-butylbromide, performing rectal retroflexion and utilizing dynamic patient position changes. The introduction of a simple bundle of measures (withdrawal time of ⩾6 min, use of hyoscine butylbromide, position change and rectal retroflexion) into colonoscopy practice has been shown to increase ADR by 2.1%.

Endoscopy technology

Optical imaging innovations and technological developments in the field of colonoscopy have attempted to increase ADRs with the introduction of high-definition endoscopes, electronic chromo-endoscopy (including narrow-band imaging), wide-angle colonoscopies and retrograde viewing devices. However, lesions located on the proximal sides of colonic folds can still be missed during standard conventional colonoscopy. Although these views may be improved with dynamic patient position change and routine retroflexion, these manoeuvres may not be effective, particularly in
narrower colonic segments, even with the use of a paediatric colonoscope or gastroscope.\textsuperscript{27,32} Colonoscopy with right-side retroflexion has been shown to increase ADR in the right colon with a small risk of adverse events.\textsuperscript{33} Transparent caps and hoods that attach to the tip of the scope have been created to hold down folds and improve visualization in the forward view. However, they can make the tip of the scope more rigid and longer, which may impair insertion in an angulated sigmoid colon.\textsuperscript{34,35}

This review considers the advances in endoscopy technology surrounding colonoscopy and current available evidence for these.

Methods
A literature search was performed using PubMed and the terms ADR, high definition colonoscopy, chomoendoscopy, narrow band imaging, Fuji Intelligent Color Enhancement, autofluorescence imaging, i-SCAN, endoscopic trimodal imaging, cap-assisted colonoscopy, Endocuff, Endocuff Vision, Full Spectrum Endoscopy, Third-Eye Retroscope, NaviAid G-EYE Balloon Colonoscope, Aer-O-Scope colonoscope, water immersion and water exchange colonoscopy. Reference lists of the resultant articles were inspected for additional relevant papers. Only systematic reviews that were published in the Cochrane library were included. Searches were carried out on all data up to June 2017. The search only included English-language articles. The authors are aware of abstract studies but these were excluded for the purposes of this review. Where possible, the highest levels of evidence have been used. Levels of evidence are graded based on “The Oxford Levels of Evidence 2”.\textsuperscript{36} Table 1 illustrates the highest level of evidence available for each modality.

Imaging

**High-definition colonoscopy**
High-definition colonoscopy is the use of a high-definition monitor and colonoscope resulting in more images per second being shown with a higher resolution compared to standard colonoscopy, thus improving image quality and potentially identifying more pathology.

Early studies did not report a significant difference in ADR when comparing high-definition colonoscopy with standard colonoscopy.\textsuperscript{37–39,41–43} The earliest positive result was a cohort study in which the total number of non-flat, >6 mm adenomas was higher in the high-definition group compared to standard colonoscopy.\textsuperscript{41} A retrospective study reported a significant increase of 4.5% in ADR in patients with high-definition colonoscopy with an up to 3% increase found in adenomas <5 mm in size. However, confounding factors such as withdrawal time and quality of bowel preparation were not standardized.\textsuperscript{40} Two recent studies have reported a significant increase in ADR (8.2\% p = 0.02, 12.6\% p = 0.007) with high-definition colonoscopy.\textsuperscript{44,45} However these were retrospective cohort studies. In conclusion, high-definition colonoscopy appears to improve ADR. However, prospective studies are required to further confirm this.

**Conventional chromo-endoscopy**
Conventional chromo-endoscopy utilizes contrast dyes that allow for enhancement of the colonic mucosa, thus improving visualization and highlighting surface contours. In conventional pan-colonic chromo-endoscopy, dye in the form of indigo carmine or methylene blue is sprayed with a catheter or is applied directly through the working channel of the endoscope in a segmental fashion onto the entire colorectal mucosa.

A Cochrane systematic review analysed seven randomized controlled trials (RCTs) with a total of 2727 participants and assessed the role of conventional chromo-endoscopy compared to standard colonoscopy in polyp detection and found that chromo-endoscopy generated more participants with at least one neoplastic lesion (OR 1.53, 95\% CI 1.31–1.79) and at least one diminutive neoplastic lesion (OR 1.51, 95\% CI 1.19–1.92).\textsuperscript{46} They concluded that conventional chromo-endoscopy improved the detection rate of small polyps by 90\%.\textsuperscript{46} Thus, chromo-endoscopy may have a role in improving ADR.

**Virtual chromo-endoscopy**
Virtual chromo-endoscopy utilizes a narrow spectrum of wavelengths with a decreased penetration depth to enhance visualization of the colonic mucosa. These narrow wavelengths increase the vascular contrast of the mucosa and allow for improved visualization of the colonic mucosal
### Table 1. Levels of evidence for devices in colonoscopy.

| Study                        | Level of evidence | Measures used | Primary outcome | Patients \(n\) | Main outcomes                                                                                                                                 |
|------------------------------|-------------------|---------------|----------------|--------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| **High-definition colonoscopy** |                   |               |                |              |                                                                                                                                             |
| Pellisé and colleagues\(^{37}\) | 2                 | SD versus HDWE | ADR           | 620          | No significant difference in ADR in both groups                                                                                             |
| Tribonias and colleagues\(^{39}\) | 2                 | SD versus HDWE | PDR           | 390          | Overall polyp rate higher in HDWE group \(5D 1.31 \pm 1.90; HDWE 1.76 \pm 2.31, p = 0.03\) No significant difference in ADR in both groups |
| Longcroft-Wheaton and colleagues\(^{37}\) | 2                 | SD versus HD  | ADR \(<10 \text{ mm in size}\) | 170          | No significant difference in ADR in both groups                                                                                             |
| Buchner and colleagues\(^{40}\) | 3                 | SD versus HD  | ADR           | 2430         | ADR 4.5% higher in HD group \(p = 0.012\) Adenomas \(1–5 \text{ mm}\) up to 3% increase ADR \(p = 0.024\) Adenomas \(6–9 \text{ mm}\) 2.5% increase ADR \(p = 0.031\) |
| East and colleagues\(^{41}\)    | 3                 | SD versus HD  | ADR           | 130          | No significant difference in ADR in both groups Total number of non-flat, small adenomas \(<6 \text{ mm}\) higher in HD group – 78 versus 60, \(p = 0.03\) |
| Burke and colleagues\(^{42}\)    | 3                 | SD versus HDWE | ADR           | 852          | No significant difference in ADR in both groups                                                                                             |
| Erim\(^{33}\)                   | 3                 | SD versus HD  | PDR           | 900          | No significant difference in ADR in both groups                                                                                             |
| Jrebi and colleagues\(^{44}\)   | 3                 | SD versus HD  | ADR, PDR      | 1268         | ADR higher in HD group \(30.4\% versus 22.2\%, \(p = 0.02\)\) PDR higher in HD group \(48.2\% versus 35.6\%, \(p < 0.001\)\) |
| Bond and colleagues\(^{45}\)    | 3                 | SD versus HD  | ADR, MAP      | 395          | ADR 12.6% higher with HD \(p = 0.007\) MAP 0.5 higher with HD \(p = 0.01\) Screening patients                                                                 |
| **Conventional chromo-endoscopy** |                   |               |                |              |                                                                                                                                             |
| Brown and colleagues\(^{46}\)   | 1                 | CE versus SD  | PDR, diminutive lesions, number of participants with multiple neoplastic lesions | 2727         | CE group found more people with at least one neoplastic lesion \(\text{odds ratio (OR) 1.53, 95\% confidence interval [CI] 1.31–1.79; 7 trials; 2727 participants, and at least one diminutive neoplastic lesion (OR 1.51, 95\% CI 1.19–1.92; 4 trials; 1757 participants)}\) |
### Table 1. (Continued)

| Study                        | Level of evidence | Measures used          | Primary outcome | Patients [n] | Main outcomes                                                                 |
|------------------------------|-------------------|------------------------|-----------------|--------------|-------------------------------------------------------------------------------|
| **Narrow-band imaging**      |                   |                        |                 |              |                                                                                |
| Nagorni and colleagues⁶⁷     | 1                 | NBI versus SD          | PDR             | 3673         | No significant difference in both groups                                       |
| Senore and colleagues⁶⁸      | 2                 | NBI versus SD          | ADR             | 117          | No significant difference in both groups                                       |
| East and colleagues⁶⁹        | 2                 | NBI versus SD          | ADR             | 214          | No significant difference in both groups                                       |
| Ikematsu and colleagues⁵⁰   | 2                 | NBI-SD versus SD-NBI   | ADR/AMR         | 813          | Lower adenoma miss rate proximal colon for NBI [21.3% versus 27.8%, \( p = 0.03 \)] |
| Adler and colleagues⁶¹       | 2                 | NBI versus SD          | ADR             | 401          | No significant difference in both groups                                       |
| Gilani and colleagues⁵²      | 2                 | SD-NBI versus NBI-SD   | ADR             | 300          | No significant difference in both groups                                       |
| Gross and colleagues⁵³       | 2                 | SD-HDNBI versus HDNBI-SD | PMR             | 96           | Polyp miss rates lower with HDNBI-SD [31% versus 57%, \( p = 0.005 \)]        |
| Rastogi and colleagues⁵⁴     | 2                 | SDWL versus HDWL versus NBI | ADR             | 630          | No significant difference in ADR in both groups NBI picked up more flat adenomas 11.4% versus 2.4% \( p < 0.001 \) |
| **Fuji Intelligent Color Enhancement** |                   |                        |                 |              |                                                                                |
| Chung and colleagues⁵⁵       | 2                 | NBI versus FICE versus WL | ADR             | 1650         | No significant difference in all three groups for ADR                           |
| Chung and colleagues⁵⁶       | 2                 | FICE-SDWL versus SDWL-FICE | AMR             | 359          | No significant difference in both groups                                       |
| Yoshida and colleagues⁵⁷     | 2                 | NBI-FICE versus FICE-NBI | AMR             | 55           | No significant difference in both groups                                       |
| Kang and colleagues⁵⁸        | 2                 | NBI versus FICE        | ADR             | 955          | No significant difference in both groups                                       |
| **Autofluorescence imaging** |                   |                        |                 |              |                                                                                |
| Zhao and colleagues⁵⁹       | 1                 | WL-AFI versus AFI- WL  | ADR, PDR, AMR, PMR | 1199         | No significant difference in both groups for ADR and PDR AFI decreases AMR and PMR significantly compared to WL [OR 0.62, 95% CI 0.44–0.86, OR 0.64; 95% CI 0.48–0.85] |
| Study                     | Level of evidence | Measures used                              | Primary outcome | Patients (n) | Main outcomes                                                                                                                                 |
|--------------------------|-------------------|--------------------------------------------|-----------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Moriichi and colleagues | 3                 | Back-to-back SD and AFI                    | ADR             | 88           | ADR increase by 8% \(p < 0.05\) in AFI group  
ADR increase in AFI 30.3% \(p < 0.05\) but only for inexperienced endoscopists \(<500\ SD and <10\ AFI\)  
Only looked at sigmoid and rectum |
| i-SCAN™                  |                   |                                            | ADR             | 220          | ADR 38% i-SCAN versus 13% SD \(p < 0.0001\)                                                                                       |
| Hoffman and colleagues   | 2                 | SD versus i-SCAN                           | ADR             | 389          | No improvement in ADR but i-SCAN effective for real-time histologic prediction of polyps                                                  |
| Hong and colleagues      | 2                 | HDWL-HDWL, i-SCAN1-HDWL, i-SCAN2-HDWL      | ADR             | 389          | No improvement in ADR but i-SCAN effective for real-time histologic prediction of polyps                                                  |
| Chan and colleagues      | 3                 | HDWL versus i-SCAN                         | Predicting polyp | 75           | No significant difference in both groups                                                                                               |
| Pigó and colleagues      | 3                 | HDWL versus histology                      | Predicting polyp | 78           | i-SCAN helps assist in real-time prediction of histology with 95% sensitivity, 82% specificity and 92% accuracy                             |
| Basford and colleagues   | 3                 | HDWL versus i-SCAN                         | Predicting polyp | 84           | No significant difference in both groups                                                                                               |
| Bowman and colleagues    | 3                 | HDWL versus i-SCAN                         | ADR             | 1936         | ADR higher with i-SCAN [618 versus 402, \(p < 0.01\)] Advanced adenomas \(\geq 10\ mm\) higher with i-SCAN \[79 versus 47, \(p = 0.021\)\]     |
| Kim and colleagues       | 3                 | HDWL versus i-SCAN                         | PDR             | 501          | PDR higher with i-SCAN [52\% versus 38.1\%, \(p = 0.004\)]                                                                            |
| Rodriguez-D’Jesus and Saperas | 3           | HDWL versus i-SCAN                         | Diagnostic yield| 155          | No significant difference                                                                                                             |
| Endoscopic trimodal imaging |               |                                            | ADR             | 234          | No significant difference in both groups                                                                                               |
| Kuiper and colleagues    | 2                 | ETMI [HRE-AFI] versus SD-SD                | ADR             | 234          | No significant difference in both groups                                                                                               |
| Van den Broek and colleagues | 2           | HRE-AFI versus AFI-HRE                     | AMR             | 100          | No significant difference in both groups                                                                                               |
| Rotondano and colleagues | 2                 | HRE-AFI versus AFI-HRE                     | AMR             | 94           | No significant difference in both groups                                                                                               |
### Cap-assisted colonoscopy

| Study                          | Level of evidence | Measures used                  | Primary outcome                                      | Patients (n) | Main outcomes                                                                 |
|-------------------------------|-------------------|--------------------------------|-------------------------------------------------------|--------------|-------------------------------------------------------------------------------|
| Morgan and colleagues\(^2\)    | 1                 | CAC versus SD                  | Efficacy of colonoscopy as diagnostic tool            | 5932         | May improve caecal intubation time, PDR and pain                              |
| Pohl and colleagues\(^3\)      | 1                 | CAC versus SD                  | ADR                                                   | 1113         | No significant difference in ADR                                              |
| Desai and colleagues\(^4\)     | 1                 | CAC versus SD                  | Right-sided ADRs                                     | 686          | Improvement in right-sided ADR with CAC [23% versus 17%, \(p = 0.01\)] *1*  |
|                               |                   |                                |                                                       |              | Improvement in flat ADRs with CAC [OR 2.08, 95% CI 1.3–3.20, \(p < 0.01\)]  |
| Rastogi and colleagues\(^5\)   | 2                 | CAC versus SD                  | ADR                                                   | 420          | Higher ADR with CAC 69% versus 56%, \(p = 0.009\)                            |
| De Wijkerslooth and colleagues\(^5\) | 2           | CAC versus SD                  | ADR                                                   | 1380         | No change in ADR but improve patient comfort scores                          |
| Othman and colleagues\(^6\)    | 2                 | CAC versus SD                  | ADR                                                   | 440          | No improvement in ADR                                                         |
|                               |                   |                                |                                                       |              | Improvement in AADR with CAC [9.9% versus 4.6%, \(p = 0.049\)]              |
| Hewett and Rex\(^7\)          | 2                 | CAC-SD versus SD-SD-CAC        | AMR                                                   | 67           | CAC lower miss rate 21% versus 33%, \(p = 0.039\) especially in diminutive adenomas \(\leq 5\) mm 22% versus 35%, \(p = 0.037\) |
| Horiuchi and colleagues\(^8\)  | 2                 | CAC versus SD                  | ADR                                                   | 107          | No significant difference in ADR                                              |
| Harada and colleagues\(^9\)    | 2                 | CAC versus SD                  | PDR, CIT, patient comfort                            | 592          | No significant change in PDR but lower patient discomfort scores             |
| Tee and colleagues\(^10\)     | 2                 | CAC versus SD                  | CIT                                                   | 400          | No change in PDR or caecal intubation time                                    |
| Frieling and colleagues\(^11\)| 2                 | CAC versus SD                  | PDR                                                   | 504          | No significant difference in PDR                                              |

### Endocuff™/Endocuff Vision™

| Study                          | Level of evidence | Measures used                  | Primary outcome   | Patients (n) | Main outcomes                                                                 |
|-------------------------------|-------------------|--------------------------------|-------------------|--------------|-------------------------------------------------------------------------------|
| Floer and colleagues\(^12\)   | 2                 | EAC versus SD                  | ADR               | 500          | ADR significantly increased 35.4% versus 20.7%, \(p < 0.0001\)               |
| Bieker and colleagues\(^13\)  | 2                 | EAC versus SD                  | PDR               | 498          | PDR increased with EAC [56% versus 42%, \(p = 0.0001\)]                    |
| Study                         | Level of evidence | Measures used                  | Primary outcome | Patients | Main outcomes                                                                                                                                                                                                 |
|------------------------------|-------------------|--------------------------------|-----------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Van Doorn and colleagues     | 2                 | EAC versus SD                  | ADR             | 1063     | No significant difference in ADR in both groups MAP was higher in EAC group (1.44 versus 1.18%, *p* = 0.036) CIT shorter in EAC group (7 min versus 8.3 min, *p* < 0.001) |
| De Palma and colleagues      | 2                 | EAC versus SD                  | ADR             | 288      | ADR improved with EAC (29.6% versus 26.3%, *p* < 0.01) Small adenomas (<5 mm) detection rate improved with EAC (129 versus 84, *p* < 0.01)                                                        |
| Bhattacharya and colleagues  | 2                 | EAC versus SD                  | ADR             | 534      | No significant difference in ADR Screening patients                                                                                                                                                          |
| Ngu and colleagues           | 2                 | EAC versus SD                  | ADR             | 1772     | ADR improved by 4.8% (*p* = 0.02) globally, 10.8% (*p* < 0.001) in patients attending via the English Bowel Cancer Screening Programme.                                                                       |
| Sawatzki and colleagues      | 3                 | EAC                            | ADR             | 104      | ADR of 47% screening population by experienced endoscopists                                                                                                                                                  |
| EndoRings™                   |                   |                                |                 |          |                                                                                                                                                                                                             |
| Dik and colleagues           | 2                 | EndoRings-SD versus SD-EndoRings| AMR             | 116      | Adenoma miss rate in EndoRings group lower (10.4% versus 48.3%, *p* < 0.001)                                                                                                                                 |
| Full spectrum endoscopy®     |                   |                                |                 |          |                                                                                                                                                                                                             |
| Grajnek and colleagues       | 2                 | SD-FUSE versus FUSE-SD         | AMR             | 185      | Adenoma miss rate lower in FUSE group 7% versus 41%, *p* < 0.0001                                                                                                                                           |
| Hassan and colleagues        | 2                 | FUSE versus SD                 | AMR             | 658      | No significant improvement in ADR                                                                                                                                                                          |
| Papanikolau and colleagues   | 2                 | SD-FUSE versus FUSE-SD         | AMR             | 215      | Adenoma miss rate lower in FUSE group 10.9% (95% CI 3.8–18.1) versus 33.7% (95% CI 23.4 versus 44.1)                                                                                                         |
| Ito and colleagues           | 3                 | FUSE                           | ADR             | 130      | No significant improvement in ADR                                                                                                                                                                          |
| Grajnek and colleagues       | 3                 | FUSE                           | Feasibility, usability, safety | 50  | Safe to use                                                                                                                                                                                                  |
| Song and colleagues          | 3                 | FUSE                           | Feasibility     | 262      | Safe to use ADR reported 36.3%                                                                                                                                                                             |

Table 1. (Continued)
| Study                                      | Level of evidence | Measures used                  | Primary outcome       | Patients (n) | Main outcomes                                      |
|-------------------------------------------|-------------------|--------------------------------|-----------------------|--------------|---------------------------------------------------|
| **Third-eye ® Retroscope ®**             |                   |                                 |                       |              |                                                   |
| Leufkens and colleagues                   | 2                 | Tandem SC-TEC versus TEC-SC     | ADR                   | 395          | Net additional ADRs 23.3% for adenomas            |
| **NaviAid™ G-EYE™ balloon colonoscope**   |                   |                                 |                       |              |                                                   |
| Halpern and colleagues                    | 2                 | SD-NaviAid versus NaviAid-SD    | AMR                   | 126          | Adenoma miss rate lower in NaviAid group 7.5% versus 44.7%, p = 0.0002 |
| Grainek and colleagues                    | 3                 | NaviAid                        | Safety and feasibility| 47           | Safe and feasible                                 |
| **Aer-O-Scope™ colonoscope**              |                   |                                 |                       |              |                                                   |
| Vucelic and colleagues                    | 4                 | Aer-o-scope                    | Extent of colonic intubation | 12           | 83% caecal intubation rate                        |
| **Water-aided (immersion/exchange) colonoscopy** |       |                                 |                       |              |                                                   |
| Hafner and colleagues                     | 1                 | Water-aided versus air insufflation | Technical quality, screening efficacy, patient acceptance | 2933        | Main benefit is reduction in procedure-related abdominal pain which may enhance acceptance of screening/surveillance colonoscopy. Some improvement in ADR likely due to cleansing effects of water |
| Cadoni and colleagues                     | 2                 | WE versus WI versus AICD       | To assess ADR in the right colon | 1200        | Water exchange colonoscopy achieved significantly higher ADR (<10 mm adenomas) in the right colon [WE 11.9% versus WI 6.9%, p = 0.016, versus AICD 7.2%, p = 0.025] |

ADR, adenoma detection rate; AICD, air insufflation colonoscopy; AMR, adenoma miss rate; CE, conventional chromo-endoscopy; EAC, Endocuff-assisted colonoscopy; ETMI, endoscopic trimodal imaging; EVAC, Endocuff Vision-assisted colonoscopy; FICE, Fuji Intelligent Color Enhancement; FUSE, full spectrum endoscopy; HD, high-definition colonoscopy; HDNBI, high-definition narrow-band imaging colonoscopy; HDWE, high-definition wide-angle colonoscopy; HDWL, high-definition white-light colonoscopy; HRE, high-resolution endoscopy; NBI, narrow-band imaging colonoscopy; PDR, polyp detection rate; SD, standard-definition colonoscopy; SDWL, standard-definition white-light colonoscopy; TEC, Third-Eye Retroscope; WE, water exchange colonoscopy; WI, water immersion colonoscopy.
surface. Different manufacturers have developed their own systems of virtual chromo-endoscopy and the use of such modalities has been proposed for characterization of colonic lesions.\textsuperscript{101}

**Narrow-band imaging (NBI) [Olympus Inc., Tokyo, Japan]**

Narrow-band imaging uses narrow-band filters placed behind the light source to eliminate red light and increase the exposure of blue and green light. Blue light (415 nm) enhances the visualization of superficial mucosal capillaries while green light (540 nm) increases the visibility of submucosal and mucosal vessels.

A Cochrane review of 11 RCTs and 3673 patients in 2012 found no evidence to suggest that NBI was significantly better than standard colonoscopy at improving detection rates in average-risk populations.\textsuperscript{47} Six successive RCTs have reflected this and shown no significant increase in ADR with NBI.\textsuperscript{48–52,54} In contrast, a single-centre RCT found higher adenoma miss rates in standard colonoscopy compared to high-definition colonoscopy utilizing NBI (49% versus 27%, \textit{p} = 0.036).\textsuperscript{55} The authors argue that because two different colonoscopes were used in tandem compared to the other previously reported studies – standard colonoscopy followed by another colonoscope with better definition and high contrast – their study was more representative of a true miss rate. There is evidence that NBI may be of benefit in high-risk population groups such as those with Lynch syndrome and hyperplastic polyposis syndrome in ADR.\textsuperscript{102,103} In Lynch syndrome, the use of NBI in the proximal colon for surveillance colonoscopies improved ADR by 15%,\textsuperscript{102} whereas NBI has been reported to significantly reduce polyp miss rate by 26% in hyperplastic polyposis syndromes.\textsuperscript{103}

Current evidence has not demonstrated that NBI significantly improves ADR in normal-risk individuals. However, NBI may be of benefit in high-risk individuals.

**Fuji Intelligent Color Enhancement (FICE) [Fujinon Inc., Saitama, Japan]**

FICE is a computed spectral estimation technology system that enhances the visibility of mucosal and vascular details by narrowing the bandwidth of light. FICE offers the endoscopist the choice of different wavelengths for optimal views.

Three tandem RCTs and one non-tandem RCT have shown no significant benefit of FICE over standard colonoscopy or NBI\textsuperscript{55–58} in improving ADR. However, in the tandem RCT by Chung and colleagues, inadequate bowel preparation in at least 50% of cases may have impacted on ADR.\textsuperscript{55} Yoshida and colleagues also reported that poor visibility was noted with FICE for blood visibility, which may affect detection of more vascu- lated adenomatous lesions.\textsuperscript{57} There is no strong evidence that FICE improves ADR.

**Autofluorescence imaging (AFI) [Olympus, Tokyo, Japan]**

Autofluorescence imaging produces real-time pseudo-colour images by a rotating filter that produces short-wavelength light. Tissue exposure to this light leads to excitation of endogenous substances and subsequent emission of fluorescent light.

A tandem prospective study of 88 patients found an ADR rise of 8% with AFI, which increased to 30.3% when performed by less experienced endoscopists.\textsuperscript{60} However, this study only looked at the rectum and sigmoid area. There are no large RCTs available yet for this modality. A recent meta-analysis of six studies with 1199 colonoscopies found no significant differences in ADR or PDR in AFI compared to WLE, but reported that AFI did significantly decrease AMR (OR 0.62; 95% CI 0.44–0.86) and PMR (OR 0.64; 95% CI 0.48–0.85).\textsuperscript{59}

More evidence is required from RCTs to determine the role of AFI in improving ADR.

**i-SCAN™ [Pentax, Tokyo, Japan]**

i-SCAN™ is another virtual chromo-endoscopy system designed to enhance surface and vascular pattern to improve optical diagnostic performance. It has three modes of image enhancement: surface enhancement, contrast enhancement and tone enhancement.

Two RCTs reported conflicting ADR results. One study showed that i-SCAN™ improved ADR by up to 25% compared to standard colonoscopy.\textsuperscript{61} However, this study compared high-definition colonoscopy and i-SCAN™ with standard-definition colonoscopy. High-definition colonoscopy has been shown to be more sensitive
in detecting small, flat polyps and therefore this may not be a true representation of i-SCAN™. Only one study compared standard colonoscopy with standard colonoscopy and i-SCAN™; this is more representative of the effectiveness of using i-SCAN™ in the average-risk population. This study concluded that there was no improvement in ADR but that i-SCAN™ played a role in real-time histology prediction of polyps.

The largest cohort study of 1936 patients reported higher ADR with i-SCAN™, including higher AADRs. However, the role of i-SCAN™ in improving ADR has not yet been proven conclusively and larger RCTs are required.

**Endoscopic trimodal imaging (ETMI) (Olympus, Tokyo, Japan)**

ETMI combines the use of high-definition endoscopy, autofluorescence imaging and narrow-band imaging during colonoscopy.

The use of ETMI in tandem colonoscopy RCTs has not been found to significantly reduce adenoma miss rates or improve ADR. One study had non-academic endoscopists while the other two RCTs were conducted at expert centres. Two of these RCTs also recruited high-risk patients with a history of previous adenomas, cancer or a positive family history of cancer. ETMI has not yet been demonstrated to improve ADR.

**Devices to attach to colonoscope**

**Cap-assisted colonoscopy**

Cap-assisted colonoscopy is the use of a transparent cap attached to the distal tip of the colonoscope to flatten colonic folds to improve mucosal visualization proximally.

There have been mixed results in RCTs evaluating the diagnostic yield of cap-assisted colonoscopy. Initial studies which often included a small sample of endoscopists and had a limited sample size showed no improvement in ADR with cap-assisted colonoscopy. Some studies utilized PDR instead of ADR as their primary outcome. A Cochrane review also concluded that cap-assisted colonoscopy increased PDR but there was not enough evidence to suggest it increased ADR as well. A further systematic review concluded that there was an improvement in right-sided adenomas with cap-assisted colonoscopy. Other studies have shown equivocal results, but they did show that cap-assisted colonoscopy improved patient comfort compared to standard colonoscopy. The CAP study utilized a two-centre, multi-endoscopist, RCT approach to determine the role of cap-assisted colonoscopy in adenoma detection. There was no significant difference found with ADR in both groups. Cap-assisted colonoscopy seemed to be of benefit for some endoscopists who experienced an increase in ADR by 20%, whereas for others there was a 15% decrease. This was not related to endoscopist experience.

Cap-assisted colonoscopy has not yet been demonstrated to convincingly improve ADR.

**Endocuff™ and Endocuff Vision™ (Arc Medical Design Ltd, Leeds, UK)**

Endocuff™ is a disposable cuff that is attached onto the distal end of the colonoscope. The first version of Endocuff™ comprised two rows of backwards-pointing flexible ‘finger like’ projections at intervals around the device circumference. The second version, called Endocuff Vision™, only has one row of these projections, which are longer.

A multicentre prospective RCT using Endocuff™ with 500 patients in Germany found an absolute increase of 14% in ADR. A Swiss pilot study demonstrated an ADR of 47% in the screening population. A recent large RCT in the Netherlands found no significant difference in ADR in the Endocuff-assisted colonoscopy group. However, MAP was significantly higher and caecal intubation time quicker in the Endocuff-assisted colonoscopy group. A UK study of screening patients using Endocuff-assisted colonoscopy reported no significant difference in ADR.

The ADENOMA study found that Endocuff Vision™ improved ADR globally by 4.7% (p=0.02) which was driven by an increase in ADR of 10.8% (p<0.001) in patients attending for colonoscopy via the English Bowel Cancer Screening Programme.

In conclusion, Endocuff Vision™ may have a role in improving ADR in the Bowel Cancer Screening population.
EndoRings™ (EndoAid Ltd, Caesarea, Israel)

EndoRings™ is a silicone endoscopic add-on device that consists of a short tube-like core with several layers of flexible circular rings. It is attached to the tip of the scope; during scope withdrawal the rings centre the scope and straighten colonic folds, thus enhancing mucosal views.

One multicentre, randomized, tandem study has been completed comparing the use of EndoRings™ with standard colonoscopy and demonstrated a lower adenoma miss rate with EndoRings™ colonoscopy. There was no significant difference in caecal intubation or withdrawal times, although total procedure time was longer in the EndoRings™ colonoscopy group due to removal of more polyps.88

The initial study suggests benefits from Endo Rings™. However, further evidence is required from RCTs.

Different types of colonoscopes

Full Spectrum Endoscopy® (FUSE)
(EndoChoice Inc., Alpharetta, GA, USA)

FUSE® is a colonoscope that allows for a high-resolution 330° ‘full spectrum’ view of the colonic lumen. It consists of a main control unit and a video colonoscope with three imagers and LED groups located at front and both sides of the flexible tip. The video images transmitted from the three cameras on the left side, front and right side of the colonoscope are displayed on three continuous monitors. The addition of the two side cameras provides a more comprehensive view of colonic mucosa and visualizes blind spots more easily.

An initial prospective single-centre pilot cohort feasibility study showed that FUSE was feasible, usable and safe.93 Following this, a multicentre, randomized, tandem colonoscopy trial illustrated that the adenoma miss rate was significantly lower in patients in the FUSE group (7% versus 41%, p < 0.0001).89 This result has been mirrored by a Greek tandem study that reported lower miss rates by 23% with FUSE. It is argued that the use of FUSE could lead to an absolute reduction of US$145 dollars per patient due to a significantly higher sensitivity associated with FUSE.104 However, a recent Italian RCT reported no statistically significant difference in ADR and AADR between FUSE and standard colonoscopy in screening programme patients.90

In conclusion, there is inconclusive evidence for the use of FUSE in reducing adenoma miss rates and further RCTs are required.

Third-eye® Retroscope® (TEC) (Avantis Medical Systems, Inc., Sunnyvale, CA, USA)

Third-eye® Retroscope® was invented to enhance the visualization of proximal colonic folds. It is a device that consists of a video processor, a single-use polarizing filter cap for colonoscope light source and a 3.5 mm flexible single-use catheter with a camera and diode light source at the tip. The TER is retroflexed at 180° after being inserted through the working channel of the colonoscope, and provides a 135° retrograde view of the colon. The TERRACE study, which was the only randomized back-to-back study of TER, found a net additional detection rate of 30% for polyps and 23% for adenomas.95

RCTs are required to assess the role of TEC in ADR improvement.

NaviAid™ G-EYE™ Balloon Colonoscope
(SMART Medical Systems, Ra’anana, Israel)

The NaviAid™ G-EYE™ colonoscope comprises a standard colonoscope with a permanently integrated, reusable balloon at the distal end of the colonoscope. It allows for the colonoscope to be withdrawn with the balloon partially inflated, thus allowing for straightening of haustral folds and improving mucosal views. In addition, the balloon can be inflated to help anchor and stabilize the colonoscope when required.

A prospective cohort study of 50 patients identified an ADR of 45% with no major complications.97 A recent tandem RCT found that the adenoma miss rate of NaviAid™ G-EYE™ colonoscopy was significantly lower (7.5% versus 44.7%, p = 0.0002) compared to standard colonoscopy.96 This was a relatively small trial of 106 patients and the same colonoscopist performed both tandem procedures and was not blinded to the technology used.
In conclusion, large RCTs are required to further investigate the role of NaviAid™ G-EYE™ Balloon Colonoscope in ADR improvement.

**Aer-O-Scope™ colonoscope (GI-View Ltd, Ramat Gan, Israel)**
The Aer-O-Scope™ consists of a disposable scanner, which is the colonoscope component, and a workstation. The disposable scanner is made up of a soft multi-lumen tube with a unique pneumatic self-propulsion system that utilizes balloons and low-pressure carbon dioxide gas. This system maximizes the views of the entire colonic mucosa, including behind haustral folds. The lens head enables 360° panoramic, omni-directional visualization on a single screen.

A pilot study of 12 patients found a promising caecal intubation rate of 83% with no complications observed.98

Larger studies are required to assess the safety and accessibility of Aer-O-Scope™ before considering its role in ADR improvement.

**Others**

**Water immersion and water exchange colonoscopy**
Water immersion colonoscopy can be used as an adjunct to air insufflation to aid insertion, and is characterized by the removal of infused water during the withdrawal phase of colonoscopy. Water exchange colonoscopy is the infusion of water during the insertion of the colonoscope without air insufflation. It is a technique in which water-containing faeces are removed and exchanged for clean water in the absence of air insufflations.

A Cochrane review of 16 RCTs and 2933 patients found the main benefit of water immersion and water exchange colonoscopy to be reduction in pain scores.99 There was also a small improvement in ADR (RR 1.16, 95% CI 1.04–1.30, \( p = 0.007 \)).99 A recent RCT of 1200 patients reported that water exchange colonoscopy achieved higher ADR (adenomas <10 mm) in the right colon of 5% compared to water immersion and 4.7% compared to air insufflation colonoscopy.100 The results are promising but further evidence for the benefit of water-aided colonoscopy from RCTs is required.

**Summary**
Optimizing mucosal visualization is fundamental to ensuring high-quality colonoscopy. High ADRs are associated with better outcomes. ADR can be improved by improving technique but may also be improved by utilizing technology. It is important that this technology is studied properly and that it can be utilized by a wide range of endoscopists, not just experts. The majority of studies for devices currently reported focus on the use of devices in procedures undertaken by expert colonoscopists and may not truly reflect all groups of colonoscopists. Some studies show a significant improvement in ADR, and it is important that ongoing research involves RCTs and focuses on the learning curves for each device and the generalizable nature of findings. As evidence for the use of devices grows, it is also important that studies comparing the various devices are undertaken to establish which are most effective and in what clinical setting. Although it is important to optimize the use of new technology, the cost and time required to train endoscopists must be considered. The learning curve to use novel approaches correctly must be understood as well as the potential for increased time to undertake procedures. Additionally, health economics analyses should be undertaken to establish the cost-effectiveness of each device. The wide range of technology may be confusing to general colonoscopists and decisions regarding application of technology should be based on high-quality evidence. Specialist and national societies have an important role in supporting clinicians as they work out the optimal technology to deliver the best outcomes for their patients.

**Funding**
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Conflict of interest statement**
We declare competing interest: Colin Rees has received research grants from ARC Medical, Olympus Medical, Aquilant Endoscopy, Norgine and travel grants from Boston Scientific and Cook Medical. He is an advisory board member for Ai4Gi.
References

1. World Cancer Research Fund International. Colorectal cancer statistics, 2015. www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics (accessed 1 January 2017).

2. US Cancer Statistics Working Group. United States cancer statistics: 1999–2012 incidence and mortality web-based report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2015.

3. Midgley R and Kerr D. Colorectal cancer. Lancet 1999; 353: 391–399.

4. Leslie A, Carey FA, Pratt NR, et al. The colorectal adenoma–carcinoma sequence. Br J Surg 2002; 89: 845–860.

5. Muto T, Bussey HJ and Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36: 2251–2270.

6. Lee TJ, Rutter MD, Blanks RG, et al. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut 2012; 61: 1050–1057.

7. Rees CJ, Bevan R, Zimmermann-Fraedrich K, et al. Expert opinions and scientific evidence for colonoscopy key performance indicators. Gut 2016; 65: 2045.

8. Rees CJ, Thomas Gibson S, Rutter MD, et al. UK key performance indicators and quality assurance standards for colonoscopy. Gut 2016; 65: 1923–1929.

9. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362: 1795–1803.

10. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014; 370: 1298–1306.

11. Barclay RL, Vicari JJ, Doughty AS, et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 355: 2533–2541.

12. Bowles CJ, Leicester R, Romaya C, et al. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow? Gut 2004; 53: 277–283.

13. Rees CJ, Rajasekhar PT, Rutter MD, et al. Quality in colonoscopy: European perspectives and practice. Expert Rev Gastroenterol Hepatol 2014; 8: 29–47.

14. van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006; 101: 343–350.

15. East JE, Saunders BP, Burling D, et al. Surface visualization at CT colonography simulated colonoscopy: effect of varying field of view and retrograde view. Am J Gastroenterol 2007; 102: 2529–2535.

16. Boroff ES, Gurudu SR, Hentz JG, et al. Polyp and adenoma detection rates in the proximal and distal colon. Am J Gastroenterol 2013; 108: 993–999.

17. Francis DL, Rodriguez-Correa DT, Buchner A, et al. Application of a conversion factor to estimate the adenoma detection rate from the polyp detection rate. Gastrointest Endosc 2011; 73: 493–497.

18. Greenspan M, Rajan KB, Baig A, et al. Advanced adenoma detection rate is independent of nonadvanced adenoma detection rate. Am J Gastroenterol 2013; 108: 1286–1292.

19. Brenner H, Altenhofen L, Kretschmann J, et al. Trends in adenoma detection rates during the first 10 years of the German Screening Colonoscopy Program. Gastroenterology 2015; 149: 356–66.e1.

20. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112: 24–28.

21. Le Clercq CMC, Bouwens MWE, Rondagh EJA, et al. Postcolonoscopy colorectal cancers are preventable: a population-based study. Gut 2014; 63: 957–963.

22. Gavin DR, Valori RM, Anderson JT, et al. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut 2013; 62: 242–249.

23. Munroe CA, Lee P, Copland A, et al. A tandem colonoscopy study of adenoma miss rates during endoscopic training: a venture into uncharted territory. Gastrointest Endosc 2012; 75: 561–567.

24. Clark BT, Rustagi T and Laine L. What level of bowel prep quality requires early repeat colonoscopy: systematic review and meta-analysis of the impact of preparation quality
on adenoma detection rate. *Am J Gastroenterol* 2014; 109: 1714–1723.

25. Lee TJ, Blanks RG, Rees CJ, et al. Longer mean colonoscopy withdrawal time is associated with increased adenoma detection: evidence from the Bowel Cancer Screening Programme in England. *Endoscopy* 2013; 45: 20–26.

26. Corte C, Dahlenburg L, Selby W, et al. Hyoscine butylbromide administered at the cecum increases polyp detection: a randomized double-blind placebo-controlled trial. *Endoscopy* 2012; 44: 917–922.

27. East JE, Bassett P, Arebi N, et al. Dynamic patient position changes during colonoscope withdrawal increase adenoma detection: a randomized, crossover trial. *Gastrointest Endosc* 2011; 73: 456–463.

28. Rajasekhar PT, Rees CJ, Bramble MG, et al. A multicenter pragmatic study of an evidence-based intervention to improve adenoma detection: the Quality Improvement in Colonoscopy (QIC) study. *Endoscopy* 2015; 47: 217–224.

29. Kaltenbach T, Friedland S and Soetikno R. A randomised tandem colonoscopy trial of narrow band imaging versus white light examination to compare neoplasia miss rates. *Gut* 2008; 57: 1406–1412.

30. Siersema PD, Rastogi A, Leufkens AM, et al. Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup. *World J Gastroenterol* 2012; 18: 3400–3408.

31. Fenlon HM, Nunes DP, Clarke PD, et al. Colorectal neoplasm detection using virtual colonoscopy: a feasibility study. *Gut* 1998; 43: 806–811.

32. Saifuddin T, Trivedi M, King PD, et al. Usefulness of a pediatric colonoscope for colonoscopy in adults. *Gastrointest Endosc* 2000; 51: 314–317.

33. Cohen J, Grunwald D, Grossberg LB, et al. The effect of right colon retroflexion on adenoma detection. *J Clin Gastroenterol* 2016; 51: 1.

34. Harada Y, Hirasawa D, Fujita N, et al. Impact of a transparent hood on the performance of total colonoscopy: a randomized controlled trial. *Gastrointest Endosc* 2009; 69: 637–644.

35. Rastogi A, Bansal A, Rao DS, et al. Higher adenoma detection rates with cap-assisted colonoscopy: a randomised controlled trial. *Gut* 2012; 61: 402–408.

36. Howick J, Chalmers I, Glasziou P, et al. OCEBM Levels of Evidence Working Group: The Oxford 2011 levels of evidence, 2011, www.cebm.net/index.aspx?o=5653 (accessed 1 January 2017).

37. Pellisé M, Fernández-Esparrach G, Cárdenas A, et al. Impact of wide-angle, high-definition endoscopy in the diagnosis of colorectal neoplasia: a randomized controlled trial. *Gastroenterology* 2008; 135: 1062–1068.

38. Tribonias G, Theodoropoulou A, Konstantinidis K, et al. Comparison of standard vs high-definition, wide-angle colonoscopy for polyp detection: a randomized controlled trial. *Colorectal Dis* 2010; 12: 260–266.

39. Longcroft-Wheaton G, Brown J, Cowlishaw D, et al. High-definition vs. standard-definition colonoscopy in the characterization of small colonic polyps: results from a randomized trial. *Endoscopy* 2012; 44: 905–910.

40. Buchner AM, Shahid MW, Heckman MG, et al. High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy. *Clin Gastroenterol Hepatol* 2010; 8: 364–370.

41. East JE, Stav vindis M, Thomas-Gibson S, et al. A comparative study of standard vs. high definition colonoscopy for adenoma and hyperplastic polyp detection with optimized withdrawal technique. *Aliment Pharmacol Ther* 2008; 28: 768–776.

42. Burke CA, Choure AG, Sanaka MR, et al. Comparison of high-definition versus conventional colonoscopes for polyp detection. *Dig Dis Sci* 2010; 55: 1716–1720.

43. Erim T. Role of high definition colonoscopy in colorectal adenomatous polyp detection. *World J Gastroenterol* 2011; 17: 4001.

44. Jrebi NY, Hefty M, Jalouta T, et al. High-definition colonoscopy increases adenoma detection rate. *Surg Endosc* 2017; 31: 78–84.

45. Bond A, O'Toole P, Fisher G, et al. New-generation high-definition colonoscopes increase adenoma detection when screening a moderate-risk population for colorectal cancer. *Clin Colorectal Cancer* 2017; 16: 44–50.

46. Brown SR, Baraza W, Din S, et al. Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum. *Cochrane Database Syst Rev* 2016; 4: CD006439.
47. Nagorni A, Bjelakovic G and Petrovic B. Narrow band imaging versus conventional white light colonoscopy for the detection of colorectal polyps. *Cochrane Database Syst Rev* 2012; 1: CD008361.

48. Senore C, Reggio D, Musso A, et al. Narrow band imaging vs. high definition colonoscopy for detection of colorectal adenomas in patients with positive faecal occult blood test: a randomised trial. *Dig Liver Dis* 2014; 46: 803–807.

49. East JE, Ignjatovic A, Suzuki N, et al. A randomized, controlled trial of narrow-band imaging vs high-definition white light for adenoma detection in patients at high risk of adenomas. *Colorectal Dis* 2012; 14: 771–778.

50. Ikematsu H, Saito Y, Tanaka S, et al. The impact of narrow band imaging for colon polyp detection: a multicenter randomized controlled trial by tandem colonoscopy. *J Gastroenterol* 2012; 47: 1099–1107.

51. Adler A, Pohl H, Papanikolaou IS, et al. A prospective randomised study on narrow-band imaging versus conventional colonoscopy for adenoma detection: does narrow-band imaging induce a learning effect? *Gut* 2008; 57: 59–64.

52. Gilani N, Stipo S, Panetta JD, et al. Polyp detection rates using magnification with narrow band imaging and white light. *World J Gastrointest Endosc* 2015; 7: 555–562.

53. Gross SA, Buchner AM, Crook JE, et al. A comparison of high definition-image enhanced colonoscopy and standard white-light colonoscopy for colorectal polyp detection. *Endoscopy* 2011; 43: 1045–1051.

54. Rastogi A, Early DS, Gupta N, et al. Randomized, controlled trial of standard-definition white-light, high-definition white-light, and narrow-band imaging colonoscopy for the detection of colon polyps and prediction of polyp histology. *Gastrointest Endosc* 2011; 74: 593–602.

55. Chung SJ, Kim D, Song JH, et al. Comparison of detection and miss rates of narrow band imaging, flexible spectral imaging chromoendoscopy and white light at screening colonoscopy: a randomised controlled back-to-back study. *Gut* 2014; 63: 785–791.

56. Chung SJ, Kim D, Song JH, et al. Efficacy of computed virtual chromoendoscopy on colorectal cancer screening: a prospective, randomized, back-to-back trial of Fuji Intelligent Color Enhancement versus conventional colonoscopy to compare adenoma miss rates. *Gastrointest Endosc* 2010; 72: 136–142.

57. Yoshida Y, Matsuda K, Sumiyama K, et al. A randomized crossover open trial of the adenoma miss rate for narrow band imaging (NBI) versus flexible spectral imaging color enhancement (FICE). *Int J Colorectal Dis* 2013; 28: 1511–1516.

58. Kang HY, Kim YS, Kang SJ, et al. Comparison of narrow band imaging and Fujinon Intelligent Color Enhancement in predicting small colorectal polyp histology. *Dig Dis Sci*. Epub ahead of print 14 April 2015. DOI: 10.1007/s10620-015-3661-5.

59. Zhao ZY, Guan YG, Li BR, et al. Detection and miss rates of autofluorescence imaging of adenomatous and polypoid lesions during colonoscopy: a systematic review and meta-analysis. *Endosc Int Open* 2015; 3: E226–E235.

60. Morichi K, Fujiya M, Sato R, et al. Back-to-back comparison of auto-fluorescence imaging (AFI) versus high resolution white light colonoscopy for adenoma detection. *BMC Gastroenterol* 2012; 12: 75.

61. Hoffman A, Sar F, Goetz M, et al. High definition colonoscopy combined with i-Scan is superior in the detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized controlled trial. *Endoscopy* 2010; 42: 827–833.

62. Hong SN, Choe WH, Lee JH, et al. Prospective, randomized, back-to-back trial evaluating the usefulness of i-SCAN in screening colonoscopy. *Gastrointest Endosc* 2012; 75: 1011–1021.e2.

63. Chan JL, Lin L, Feiler M, et al. Comparative effectiveness of i-SCAN™ and high-definition white light characterizing small colonic polyps. *World J Gastroenterol* 2012; 18: 5905–5911.

64. Pigó F, Bertani H, Manno M, et al. i-Scan high-definition white light endoscopy and colorectal polyps: prediction of histology, interobserver and intraobserver agreement. *Int J Colorectal Dis* 2013; 28: 399–406.

65. Basford PJ, Longcroft-Wheaton G, Higgins B, et al. High-definition endoscopy with i-Scan for evaluation of small colon polyps: the HiSCOPE study. *Gastrointest Endosc* 2014; 79: 111–118.

66. Bowman EA, Pfau PR, Mitra A, et al. High definition colonoscopy combined with i-SCAN imaging technology is superior in the detection of adenomas and advanced lesions compared to high definition colonoscopy alone. *Diagn Ther Endosc* 2015; 2015: 1–5.
67. Kim WJ, Park SY, Park I, et al. Increased detection of colorectal polyps in screening colonoscopy using high definition i-SCAN compared with standard white light. *Clin Endosc* 2016; 49: 69–75.

68. Rodriguez-D’Jesus A and Saperas E. Enhanced flat adenoma detection rate with high definition colonoscopy plus i-SCAN for average-risk colorectal cancer screening. *Rev Esp Enferm Dig* 2016; 108: 257–262.

69. Kuiper T, van den Broek FJC, Naber AH, et al. Endoscopic trimodal imaging detects colonic neoplasia as well as standard video endoscopy. *Gastroenterology* 2011; 140: 1887–1894.

70. van den Broek FJC, Fockens P, Van Eeden S, et al. Clinical evaluation of endoscopic trimodal imaging for the detection and differentiation of colonic polyps. *Clin Gastroenterol Hepatol* 2009; 7: 288–295.

71. Rotondano G, Bianco MA, Sansone S, et al. Trimodal endoscopic imaging for the detection and differentiation of colorectal adenomas: a prospective single-centre clinical evaluation. *Int J Colorectal Dis* 2012; 27: 331–336.

72. Morgan J, Thomas K, Lee-Robichaud H, et al. Transparent cap colonoscopy versus standard colonoscopy for investigation of gastrointestinal tract conditions. Chichester: Wiley.

73. Pohl H, Bensen SP, Toor A, et al. Cap-assisted colonoscopy and detection of adenomatous polyps (CAP) study: a randomized trial. *Endoscopy* 2015; 47: 891–897.

74. Desai M, Sanchez-Yague A, Choudhary A, et al. Impact of cap-assisted colonoscopy on detection of proximal colon adenomas: systematic review and meta-analysis. *Gastrointest Endosc*. Epub ahead of print 29 March 2017. DOI: 10.1016/j.gie.2017.03.1524.

75. de Wijkerslooth TR, Stoop EM, Bossuyt PM, et al. Adenoma detection with cap-assisted colonoscopy versus regular colonoscopy: a randomised controlled trial. *Gut* 2012; 61: 1426–1434.

76. Othman MO, Zhang D, Elhanafi S, et al. Cap-assisted colonoscopy increases detection of advanced adenomas and polyps. *Am J Med Sci* 2017; 353: 367–373.

77. Hewett DG and Rex DK. Cap-fitted colonoscopy: a randomized, tandem colonoscopy study of adenoma miss rates. *Gastrointest Endosc* 2010; 72: 775–781.

78. Horiuchi A, Nakayama Y, Kato N, et al. Hood-assisted colonoscopy is more effective in detection of colorectal adenomas than narrow-band imaging. *Clin Gastroenterol Hepatol* 2010; 8: 379–383.

79. Tee HP, Corte C, Al-Ghamdi H, et al. Prospective randomized controlled trial evaluating cap-assisted colonoscopy vs standard colonoscopy. *World J Gastroenterol* 2010; 16: 3905–3910.

80. Frieling T, Neuhaus F, Kuhlbusch-Zicklam R, et al. Prospective and randomized study to evaluate the clinical impact of cap assisted colonoscopy (CAC). *Z Gastroenterol* 2013; 51: 1383–1388.

81. Floer M, Biecker E, Fitzlaff R, et al. Higher adenoma detection rates with Endocuff-assisted colonoscopy: a randomized controlled multicenter trial. *PLoS One* 2014; 9: e114267.

82. Biecker E, Floer M, Heinecke A, et al. Novel Endocuff-assisted colonoscopy significantly increases the polyp detection rate: a randomized controlled trial. *J Clin Gastroenterol* 2015; 49: 413–418.

83. van Doorn SC, van der Vlugt M, Depla A, et al. Adenoma detection with Endocuff colonoscopy versus conventional colonoscopy: a multicentre randomised controlled trial. *Gut* 1. Epub ahead of print 16 December 2015. DOI: 10.1136/gutjnl-2015-310097.

84. De Palma GD, Giglio MC, Bruzzese D, et al. Cap cuff-assisted colonoscopy versus standard colonoscopy for adenoma detection: a randomized back-to-back study. *Gastrointest Endosc*. Epub ahead of print 9 January 2017. DOI: 10.1016/j.gie.2016.12.027.

85. Bhattacharyya R, Chedgy F, Kandiah K, et al. Endocuff-assisted vs. standard colonoscopy in the fecal occult blood test-based UK Bowel Cancer Screening Programme (E-cap study): a randomized trial. *Endoscopy*. Epub ahead of print 14 June 2017. DOI: 10.1055/s-0043-111718.

86. Ngu WS, Bevan R, Tsiamoulos Z, et al. Improved adenoma detection with Endocuff Vision: The ADENOMA randomised controlled trial. *Gut* (accepted and in press).

87. Sawatzki M, Meyenberger C, Marbet UA, et al. Prospective Swiss pilot study of Endocuff-assisted colonoscopy in a screening population. *Endosc Int Open* 2015; 3: E236–E239.

88. Dik VK, Gralnek IM, Segol O, et al. Multicenter, randomized, tandem evaluation of EndoRings colonoscopy: results of the
CLEVER study. *Endoscopy*. Epub ahead of print 28 July 2015. DOI: 10.1055/s-0034-1392421.

89. Gralnek IM, Siersema PD, Halpern Z, *et al.* Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial. *Lancet Oncol* 2014; 15: 353–360.

90. Hassan C, Senore C, Radaelli F, *et al.* Full-spectrum (FUSE) versus standard forward-viewing colonoscopy in an organised colorectal cancer screening programme. *Gut* 2017; 66: 1949–1955.

91. Papanikolaou I, Apostolopoulos P, Tziatzios G, *et al.* Lower adenoma miss rate with FUSE vs. conventional colonoscopy with proximal retroflexion: a randomized back-to-back trial. *Endoscopy* 2017; 49: 468–475.

92. Ito S, Hotta K, Imai K, *et al.* Preliminary experience using full-spectrum endoscopy for colorectal cancer screening: matched case controlled study. *Gastroenterol Res Pract* 2016; 2016: 1–5.

93. Gralnek IM, Segol O, Suissa A, *et al.* A prospective cohort study evaluating a novel colonoscopy platform featuring full-spectrum endoscopy. *Endoscopy* 2013; 45: 697–702.

94. Song JY, Cho YH, Kim MA, *et al.* Feasibility of full-spectrum endoscopy: Korea’s first full-spectrum endoscopy colonoscopic trial. *World J Gastroenterol* 2016; 22: 2621.

95. Leufkens AM, DeMarco DC, Rastogi A, *et al.* Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. *Gastrointest Endosc* 2011; 73: 480–489.

96. Halpern Z, Gross SA, Gralnek IM, *et al.* Comparison of adenoma detection and miss rates between a novel balloon colonoscope and standard colonoscopy: a randomized tandem study. *Endoscopy* 2015; 47: 238–244.

97. Gralnek IM, Suissa A and Domanov S. Safety and efficacy of a novel balloon colonoscope: a prospective cohort study. *Endoscopy* 2014; 46: 883–887.

98. Vucelic B, Rex D, Pulanic R, *et al.* The Aer-o-Scope: proof of concept of a pneumatic, skill-independent, self-propelling, self-navigating colonoscope. *Gastroenterology* 2006; 130: 672–677.

99. Hafner S, Zolk K, Radaelli F, *et al.* Water infusion versus air insufflation for colonoscopy. *Cochrane Database Syst Rev* 2015; 5: CD009863.

100. Cadoni S, Falt P, Sanna S, *et al.* Impact of colonoscopy insertion techniques on adenoma detection. *Dig Dis Sci*. Epub ahead of print 5 February 2016. DOI: 10.1007/s10620-016-4053-1.

101. Wanders LK, East JE, Uitentuis SE, *et al.* Diagnostic performance of narrowed spectrum endoscopy, autofluorescence imaging, and confocal laser endomicroscopy for optical diagnosis of colonic polyps: a meta-analysis. *Lancet Oncol* 2013; 14: 1337–1347.

102. East JE, Suzuki N, Stavrinidis M, *et al.* Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer. *Gut* 2007; 57: 65–70.

103. Boparai KS, van den Broek FJ, van Eeden S, *et al.* Increased polyp detection using narrow band imaging compared with high resolution endoscopy in patients with hyperplastic polyposis syndrome. *Endoscopy* 2011; 43: 676–682.

104. Hassan C and Gralnek IM. Cost-effectiveness of ‘full spectrum endoscopy’ colonoscopy for colorectal cancer screening. *Dig Liver Dis* 2015; 47: 390–394.